2016-03-15T00:00:00.000-04:00
compelling valuation,0.593623
Pacific Biosciences shares,0.593623
metastatic urothelial carcinoma,-0.372154
Buy rating,0.407929
price target,0.407929
surgery,-0.408556
cerebrospinal fluid assay,0.401619
biosimilar delays,-0.360267
Roche,0.314525
ongoing development,0.401619
Urothelial carcinoma accounts,-0.699269
platinum-based chemotherapy,-0.390355
Priority Review,-0.372154
stock price,0.499876
metastatic setting,-0.372154
key marker,-0.757704
bladder cancers,-0.699269
renal pelvis,-0.699269
disease progression,-0.372154
Eli Lilly,0.223852
new test,0.368062
great entry point,0.499876
Johnson,0.233877
AbbVie,0.213883
7.4M Americans,-0.387843
